Cervical Cancer
Conditions
Keywords
cervical adenocarcinoma, cervical adenosquamous cell carcinoma, cervical squamous cell carcinoma, stage IB cervical cancer, stage IIA cervical cancer, stage IIB cervical cancer, stage III cervical cancer, stage IVA cervical cancer, recurrent cervical cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin followed by cisplatin and radiation therapy works in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer.
Detailed description
OBJECTIVES: Primary * Determine the response rate, in terms of clinical or radiologic response at 12 weeks after completion of study therapy, in patients with stage IB2-IVA cervical cancer treated with neoadjuvant chemotherapy comprising dose-dense paclitaxel and carboplatin followed by radical chemoradiotherapy comprising concurrent cisplatin and radiotherapy. Secondary * Determine the response rate in patients treated with this neoadjuvant chemotherapy regimen. * Determine the toxicity of this neoadjuvant chemotherapy regimen in these patients. * Assess the progression-free survival of patients treated with this regimen. * Determine the overall survival of patients treated with this regimen. OUTLINE: This is a multicenter study. * Neoadjuvant chemotherapy: Patients receive neoadjuvant chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats weekly for up to 6 courses in the absence of disease progression or unacceptable toxicity. * Chemoradiotherapy: Beginning in week 7, or as soon as blood counts recover, patients receive cisplatin IV over 1 hour on day 1. Treatment repeats weekly for 4-6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo concurrent radiotherapy comprising pelvic external beam radiotherapy once daily for 5½ weeks (5 weeks for patients with positive para-aortic lymph nodes) and 2 applications of high-dose rate intracavitary brachytherapy or low- or medium-dose rate brachytherapy. Patients with parametrial or pelvic sidewall disease extension also undergo external boost radiotherapy for 3 days. After completion of study therapy, patients are followed periodically for 2 years. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Interventions
DRUGcarboplatin
DRUGcisplatin
DRUGpaclitaxel
PROCEDUREneoadjuvant therapy
RADIATIONbrachytherapy
RADIATIONradiation therapy
Sponsors
University College London Hospitals
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed carcinoma of the cervix, including any of the following subtypes: * Squamous cell carcinoma * Adenocarcinoma * Adenosquamous cell carcinoma * Locally advanced disease (i.e., FIGO stage IB2-IVA disease) * Stage confirmed by examination under anesthesia, cystoscopy, and sigmoidoscopy with biopsy of any suspicious lesions in the bladder, vagina, or rectum * Disease suitable for treatment with radical intent using chemoradiotherapy PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Platelet count \> 100,000/mm\^3 * Hemoglobin \> 12.5 g/dL * WBC \> 3,000/mm\^3 * Absolute neutrophil count \> 1,500/mm\^3 * Bilirubin \< 1.25 times upper limit of normal (ULN) * Glomerular filtration rate (GFR) normal by ethylenediaminetetraacetic acid (EDTA) OR creatinine clearance ≥ 60 mL/min * Placement of ureteric stents required for all patients with hydronephrosis, regardless of renal function * ALT or AST \< 2.5 times ULN * Not pregnant or nursing * Negative pregnancy test * No prior diagnosis of cancer, except basal cell skin cancer * No active cardiac disease * Deemed fit to receive chemoradiotherapy * ECG normal PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate at the end of chemoradiotherapy (i.e., 12 weeks after completion of study therapy) | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate at the end of neoadjuvant treatment (i.e., 6 weeks after study entry) | — |
| Toxicity as assessed by NCI CTCAE v3.0 | — |
| Progression-free survival | — |
| Overall survival | — |
Countries
United Kingdom
Outcome results
None listed